VectorY CEO Sander van Deventer (L) and Forbion partner Wouter Joustra
November 13, 2023 09:30 AM EST
Financing
Startups

Neu­rode­gen­er­a­tive dis­ease-fo­cused Vec­to­rY nabs $138M to bring ALS vec­tor­ized an­ti­body to clin­ic

Katherine Lewin

News Reporter

Seed­ed by Eu­ro­pean VC firm For­bion in 2021, vec­tor­ized an­ti­body start­up Vec­to­rY has an­oth­er $138 mil­lion to work with in a Se­ries A co-led once …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Sage sues Bio­gen days af­ter $469M buy­out of­fer

FDA ap­proves As­traZeneca and Dai­ichi Sankyo’s ADC for breast can­cer de­spite lack of sur­vival ben­e­fit

Ozem­pic makes list for next round of Medicare drug price ne­go­ti­a­tions

Roche's car­diometa­bol­ic chief warns against weight loss 'ob­ses­sion' with GLP-1s

What Trump's CMS can and can't change with the sec­ond round of drug price ne­go­ti­a­tions

#JPM25 live blog day 1: How will Trump 2.0 im­pact the bio­phar­ma in­dus­try? Scott Got­tlieb, Bob Nelsen share ...

A service from the Financial Times